Kymab Limited

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development.